Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China

Aim To compare the proportion of participants with type 2 diabetes (T2D) treated with once‐weekly (OW) subcutaneous (SC) semaglutide versus comparators who achieved a composite metabolic endpoint. Materials and Methods SUSTAIN 1‐5, 7‐10 and SUSTAIN China trial data were pooled. Participants with T2D...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2024-01, Vol.26 (1), p.233-241
Main Authors: Ji, Linong, Ahmann, A. J., Ahrén, B., Capehorn, M. S., Hu, P., Lingvay, I., Liu, W., Rodbard, H. W., Shen, Z., Sorli, C.
Format: Article
Language:English
Subjects:
Antidiabetics
Blood pressure
cardiovascular disease
Cholesterol
clinical trial
Clinical trials
Diabetes
diabetes complications
Diabetes mellitus (non-insulin dependent)
GLP‐1 analogue
Hemoglobin
Metabolism
Regression analysis
semaglutide
type 2 diabetes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To compare the proportion of participants with type 2 diabetes (T2D) treated with once‐weekly (OW) subcutaneous (SC) semaglutide versus comparators who achieved a composite metabolic endpoint. Materials and Methods SUSTAIN 1‐5, 7‐10 and SUSTAIN China trial data were pooled. Participants with T2D (aged ≥18 years) and glycated haemoglobin ≥7.0% (≥53 mmol/mol) who had been randomized to OW SC semaglutide (0.5 or 1.0 mg) or comparator in addition to background medication. Using patient‐level data pooled by treatment, proportions of participants achieving the metabolic composite endpoint, defined as glycated haemoglobin
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.15309